Intellia Therapeutics to Present at August Healthcare Investor Conference
CAMBRIDGE, Mass., July 30, 2019 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, will present at the following upcoming healthcare conference in August:
Wednesday, August 7, 2019
SVB Leerink Spotlight Series: Rare & Genetic Diseases Conference
Location: Boston, MA
Time: 8:30am ET
About Intellia Therapeutics
Intellia Therapeutics is a leading genome editing company focused on developing proprietary, curative therapeutics using the CRISPR/Cas9 system. Intellia believes the CRISPR/Cas9 technology has the potential to transform medicine by permanently editing disease-associated genes in the human body with a single treatment course, and through improved cell therapies that can treat cancer and immunological diseases, or can replace patients’ diseased cells. The combination of deep scientific, technical and clinical development experience, along with its leading intellectual property portfolio, puts Intellia in a unique position to unlock broad therapeutic applications of the CRISPR/Cas9 technology and create a new class of therapeutic products. Learn more about Intellia Therapeutics and CRISPR/Cas9 at and follow us on Twitter @intelliatweets.
Intellia Contacts:
Investors:
Lina Li
Associate Director
Investor Relations
Media:
Jennifer Mound Smoter
Senior Vice President
External Affairs & Communications
